Vasculitic neuropathy refers to peripheral neuropathy caused by inflammation of small and medium-sized vessels supplying nerves. The classical clinical presentation is mononeuritis multiplex — sequential, often painful damage to multiple individual nerves in different limbs — but it can also present as distal symmetric polyneuropathy or focal mononeuropathy. Recognition is critical because vasculitic neuropathy is treatable; missed or undertreated, it produces permanent neurologic disability. Nerve biopsy with vasculitis on histology provides definitive diagnosis when clinical and serological features are ambiguous. This page covers vasculitic neuropathies and the broader spectrum of inflammatory neuropathies.

Classification

Primary Vasculitis (Without Systemic Disease)

  • Non-systemic vasculitic neuropathy (NSVN): vasculitis confined to peripheral nerves; treatable.

Systemic Vasculitis Involving Nerves

  • Polyarteritis nodosa (PAN): medium-vessel vasculitis; hepatitis B-associated subset; classical mononeuritis multiplex.
  • Granulomatosis with polyangiitis (GPA, Wegener): ANCA-positive (PR3); small vessel; respiratory + renal + nerve.
  • Microscopic polyangiitis (MPA): ANCA-positive (MPO); small vessel.
  • Eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss): asthma + eosinophilia + vasculitis.
  • IgA vasculitis (Henoch-Schönlein): rarely affects nerves.
  • Cryoglobulinemic vasculitis: hepatitis C-associated.

Vasculitis Associated with Connective Tissue Disease

  • Rheumatoid vasculitis.
  • Lupus.
  • Sjögren syndrome.
  • Scleroderma.

Vasculitis Associated with Other Conditions

  • Paraneoplastic vasculitis.
  • Drug-induced.
  • Infection-associated (HIV, hepatitis B and C).
  • Diabetic vasculitis (some authors include diabetic lumbosacral radiculoplexus neuropathy).

Clinical Features

Mononeuritis Multiplex (Most Common)

  • Sequential involvement of multiple named nerves.
  • Often painful at onset.
  • Asymmetric distribution.
  • Sensory + motor.
  • Common nerves: peroneal, ulnar, median, tibial.

Distal Symmetric Polyneuropathy

  • Symmetric, often with severe pain.
  • Both sensory and motor.
  • Can be confused with diabetic or other axonal polyneuropathies.

Focal Mononeuropathy

  • Less common; isolated single nerve.

Pathology

Necrotizing Vasculitis

  • Fibrinoid necrosis: vessel wall replaced by acellular fibrin-rich material.
  • Mixed cellular inflammation: neutrophils, lymphocytes, sometimes eosinophils (EGPA).
  • Vessel destruction.
  • Aneurysm formation at sites of severe damage.
  • Thrombosis.

Granulomatous Vasculitis

  • Granulomas in vessel wall.
  • GPA, EGPA characteristic.

Nerve Damage

  • Ischemic axonal damage (Wallerian-like) in affected fascicles.
  • Variable fascicle involvement (mononeuritis multiplex pattern).
  • Macrophage clearing of myelin debris.
  • Regeneration clusters in chronic phase.

Hemosiderin

Hemorrhage at sites of past vasculitis; Prussian blue positive.

Diagnosis

Workup

  • Clinical history and physical examination.
  • EMG/NCS: shows axonal pattern with asymmetric features.
  • Serologic workup: ANCA (PR3, MPO), ANA, RF, complement, hepatitis B/C, cryoglobulins, HIV.
  • Inflammatory markers: ESR, CRP.
  • Imaging: CT/MRI of chest, abdomen for systemic disease.
  • Skin biopsy if rash present.
  • Sural nerve biopsy: gold standard for definitive diagnosis.
  • Muscle biopsy concurrent with nerve biopsy in selected cases.

Nerve Biopsy Interpretation

  • Look for fibrinoid necrosis, inflammation in vessel walls, asymmetric fascicular involvement, hemosiderin.
  • Sensitivity is incomplete (involvement is patchy); negative biopsy does not exclude vasculitis.
  • Concurrent muscle biopsy increases yield.

Treatment

  • Corticosteroids: high-dose initial (often IV pulse methylprednisolone, then oral prednisone).
  • Steroid-sparing immunosuppressives: cyclophosphamide (induction in severe), methotrexate, azathioprine, mycophenolate.
  • Rituximab: alternative to cyclophosphamide for ANCA-associated vasculitis; standard for refractory.
  • Plasma exchange: severe or rapidly progressive disease.
  • Treat underlying cause (e.g., hepatitis B/C for cryoglobulinemic; cancer for paraneoplastic).
  • Pain management for neuropathic pain.
  • Long-term immunosuppression often needed; relapse risk.

Prognosis

  • Variable.
  • Early diagnosis and aggressive treatment improve outcome.
  • Many patients have partial or substantial recovery.
  • Permanent neurologic deficits common with delayed treatment.
  • Treatment-related complications (infection, malignancy, osteoporosis) important consideration.

Other Inflammatory Neuropathies

Guillain-Barré Syndrome (GBS)

  • Acute inflammatory demyelinating polyneuropathy (AIDP, most common subtype) — preceded by infection (Campylobacter, viral) often.
  • Axonal variants: AMAN (acute motor axonal neuropathy), AMSAN.
  • Miller Fisher variant: ataxia + ophthalmoplegia + areflexia; anti-GQ1b antibodies.
  • Pathology: macrophage-mediated demyelination, perivascular inflammation, complement deposition.
  • Treatment: IVIG or plasma exchange (within 4 weeks of onset); supportive ICU care.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  • Chronic progressive or relapsing demyelinating neuropathy.
  • Symmetric proximal and distal weakness + sensory features.
  • Pathology: macrophage-mediated demyelination + onion bulb formation + endoneurial edema.
  • Treatment: corticosteroids, IVIG, plasma exchange (effective in most), then maintenance immunosuppression.
  • Efgartigimod (FcRn inhibitor): approved 2024 for CIDP; new mechanism.

Multifocal Motor Neuropathy (MMN)

  • Pure motor; asymmetric; conduction blocks.
  • Anti-GM1 antibodies common.
  • Treat with IVIG; not steroid responsive.

Paraproteinemic Neuropathies

  • MGUS-associated (IgM, IgG, IgA): chronic distal sensory neuropathy.
  • Anti-MAG antibody neuropathy: chronic distal demyelinating with ataxia.
  • POEMS syndrome: Polyneuropathy + Organomegaly + Endocrinopathy + M protein + Skin changes.
  • Multiple myeloma, Waldenström macroglobulinemia-associated.

Paraneoplastic Neuropathies

  • Anti-Hu (sensory neuronopathy with SCLC).
  • Anti-CV2/CRMP5.
  • Anti-amphiphysin.
  • Cancer-associated vasculitis.

Diabetic Neuropathies

  • Distal symmetric polyneuropathy (most common).
  • Diabetic lumbosacral radiculoplexus neuropathy (DLRPN, Bruns-Garland).
  • Diabetic thoracic radiculoneuropathy.
  • Mononeuropathies (CN III, peroneal).
  • Autonomic neuropathy.

🔍 Did You Know?

The classical clinical syndrome of mononeuritis multiplex — sequential, often painful damage to multiple named peripheral nerves in different limbs over days to weeks — is one of the most clinically actionable patterns in neurology. The phrase describes the clinical pattern, but the underlying mechanism is almost always multifocal nerve infarction from vasculitis. The vasculitis can be primary (non-systemic vasculitic neuropathy), part of a systemic vasculitis (ANCA-associated, PAN, EGPA), associated with connective tissue disease, cryoglobulinemic, or paraneoplastic. Recognition of mononeuritis multiplex pattern should trigger an aggressive workup: ANCA, ANA, hepatitis B and C serology, HIV, cryoglobulins, paraneoplastic antibodies, and often sural nerve biopsy for confirmation. The treatment is similarly aggressive: high-dose corticosteroids plus a steroid-sparing immunosuppressive (cyclophosphamide or rituximab in severe cases). The clinical impact is immediate — early treatment prevents permanent neurologic disability and may be life-saving when systemic vasculitis is missed. The lesson: asymmetric, painful, sequential nerve involvement should always raise the question of vasculitic neuropathy, and the diagnostic workup must be expedited because effective treatment exists. Months of “diabetic neuropathy” workup in a patient with vasculitis can result in permanent disability that aggressive immunosuppression would have prevented.

Pitfalls and Pearls

  • Vasculitic neuropathy: fibrinoid necrosis of small/medium vessels + multifocal nerve infarction.
  • Mononeuritis multiplex: asymmetric, painful, sequential nerve involvement; vasculitis until proven otherwise.
  • Non-systemic vasculitic neuropathy (NSVN): confined to nerves; treatable.
  • ANCA-associated (GPA, MPA, EGPA): serologic workup essential.
  • PAN: medium-vessel vasculitis; hepatitis B subset.
  • EGPA (Churg-Strauss): asthma + eosinophilia + vasculitis + mononeuritis multiplex.
  • Cryoglobulinemic vasculitis: hepatitis C-associated.
  • Sural nerve biopsy: gold standard for vasculitic neuropathy.
  • Treatment: high-dose steroids + cyclophosphamide or rituximab.
  • GBS: acute; IVIG or PE; ICU.
  • Miller Fisher: ataxia + ophthalmoplegia + areflexia; anti-GQ1b.
  • CIDP: chronic; steroids/IVIG/PE; efgartigimod approved 2024.
  • MMN: pure motor; anti-GM1; IVIG only.
  • POEMS syndrome: polyneuropathy + organomegaly + endocrinopathy + M protein + skin.
  • Diabetic LRPN (Bruns-Garland): painful subacute proximal leg weakness in older diabetic with weight loss.
  • Anti-Hu paraneoplastic sensory neuronopathy: SCLC; severe sensory ataxia.

References

  1. Collins MP, Periquet MI. Non-systemic vasculitic neuropathy. Curr Opin Neurol. 2004;17(5):587-598.
  2. Said G, Lacroix C. Primary and secondary vasculitic neuropathy. J Neurol. 2005;252(6):633-641.
  3. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005;366(9497):1653-1666.
  4. Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force. Eur J Neurol. 2021;28(11):3556-3583.
  5. Allenbach Y, Vasconcelos MJ, Léger JM. Multifocal motor neuropathy: 2024 update. Curr Opin Neurol. 2024;37(5):582-588.
  6. Dispenzieri A. POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol. 2019;94(7):812-827.